In the following video, Motley Fool health-care analyst David Williamson looks at two major pieces of news surrounding biotech company Gilead (GILD 0.64%) that show that the company has a bright future ahead. He discusses another 100% cure rate for the company in the hepatitis-C space, and a new once-daily HIV drug for the company, with a better safety profile than the competition.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
This Biotech's Run Is Far From Done
By Dave Williamson
–
Mar 5, 2013 at 5:48PM
NASDAQ: GILD
Gilead Sciences
Market Cap
$135B
Today's Change
(0.64%) $0.69
Current Price
$108.69
Price as of June 20, 2025, 3:58 p.m. ET
Two pieces of news that show Gilead still has plenty of room to run.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Johnson & Johnson and owns shares of Johnson & Johnson. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Gilead Sciences
GILD
$108.69
(0.64%)
$0.69
Johnson & Johnson
JNJ
$149.81
(-0.61%)
$0.92
Bristol Myers Squibb
BMY
$46.86
(0.04%)
$0.02
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why Gilead Sciences Stock Tumbled on Tuesday
Why Gilead Sciences Stock Slipped Today
Why Gilead Sciences Stock Is Jumping Today
Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript
Gilead Sciences Beats Q4 EPS Forecast
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.